Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV–GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Carolina Digital Repository (University of North Carolina at Chapel Hill)

Topics

Biology

Immunology

Medicine

Genetics

Biotechnology

Show all topics

DOI

10.17615/ffwd-1198

License

CC-BY-NC

Other Formats

PDF